



17 June 2020

SHARE PURCHASE PLAN AND INVITATION – SHAREHOLDER VIDEO/TELECONFERENCE

Medlab Clinical Ltd (ASX: MDC) is pleased to advise that the previously announced (15 June 2020) Share Purchase Plan (SPP) is now open and SPP booklets will be dispatched today.

In addition, Medlab will be hosting a video/teleconference via a Zoom webinar to provide a company update. The call will be held Monday 29 June 2020 at 10am (Canberra, Melbourne, Sydney).

The call will be hosted by CEO, Dr Sean Hall and gives shareholders a chance to understand recent developments and have an opportunity to ask questions. Video and/or audio access will be available through Zoom.

Delegates are recommended to logon 10 minutes prior to ensure system compatibility. Spaces are limited and offered on a first come, first served basis.

Please click the link below to join the webinar:

<https://medlab.zoom.us/j/91591862296>

Or iPhone one-tap :

Australia: +61871501149,,91591862296# or +61280156011,,91591862296#

Or dial by a number based on your location (no video presentation)

Australia: +61 8 7150 1149 or +61 2 8015 6011 or +61 3 7018 2005

The Webinar ID: 915 9186 2296

For and behalf of the Board.

Alan Dworkin
Company Secretary

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: DR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.



Medlab Clinical Limited – Share Purchase Plan

Share Purchase Plan – Offer

Eligible Shareholders have the opportunity to participate in the Offer by applying for up to AUD30,000 worth of Shares without incurring brokerage, commissions, stamp duty or other transaction costs. Details of the Offer and how to participate are set out in these Terms and Conditions. Shares issued under the Offer will rank equally in all respect with all other Shares on issue as at the date of issue and will carry the same voting rights, dividend rights and other entitlements as those Shares.

Share Purchase Plan – Key Dates

Events	Dates
Record Date (being the business day prior to Medlab's announcement of the Plan)	5pm (Sydney time), Friday, 12 June 2020
Medlab announcement of Plan	Monday, 15 June 2020
Opening Date, dispatch of SPP Plan	9am (Sydney time) Wednesday, 17 June 2020
Closing Date	5pm (Sydney time) Friday, 3 July 2020
Issue Date	Tuesday, 7 July 2020
Date on which Shares issued under the Offer are expected to commence trading on the ASX	Wednesday, 8 July 2020
Despatch of holding statements in respect of Shares issued under the Offer	Thursday, 9 July 2020

Note: Medlab reserves the right to vary the dates and times set out above subject to the Corporations Act and other applicable laws.



Chairman's Letter

17 June 2020

Dear Shareholders

Medlab Clinical Limited Share Purchase Plan

I am pleased to invite you to participate in the offer of fully paid ordinary shares (**Shares**) in Medlab Clinical Limited (ACN 169 149 071) (**Medlab**) under the share purchase plan (**Plan**) established by Medlab (**Offer**).

Medlab is seeking to raise up to AUD4,000,000¹ under the Offer.

On 15 June 2020, Medlab conducted an institutional placement to professional and sophisticated investors (**Placement**) and announced the Offer. Medlab also provided a Company update on key issues relating to its business. For further information, please refer to Medlab's ASX releases lodged on 11 June 2020 and 15 June 2020.

Overview of the Offer

The Offer provides you, as an Eligible Shareholder of Medlab (subject to certain conditions), with the opportunity to acquire up to, in aggregate, AUD30,000 of Shares in Medlab at an issue price of AUD\$0.15 per Share (**Issue Price**). This price is the same as the offer price under the Placement.

To the extent that it may be necessary to scale back the number of Shares under the Plan, Medlab reserves the right to scale back applications in its sole discretion. If applications are scaled back, excess funds will be returned to applicants without interest.

Participation in the Offer is optional and is open to Eligible Shareholders who, as at Friday, 12 June 2020 (**Record Date**), were registered as holders of ordinary shares in Medlab and whose address on the share register is in Australia.

If an Eligible Shareholder holds shares as a 'custodian' (as that term is defined in *ASIC Corporations (Share and Interest Purchase Plan) Instrument 2019/547*) the Offer is also being made to the 'custodian' and, subject to a number of conditions, the 'custodian' has the discretion to extend the Offer to the relevant beneficiaries.

In addition to funding the costs of the offer, the proceeds of the Offer will be applied to:

- support the path of NanaBis™ to Phase 3 trials submission are uninterrupted – this is a key valuation milestone
- provide funding to bridge multiple research catalysts over next 12 months
- working capital for VMS inventory to maintain sales and promote new sales channels
- working capital for NanaBis™ inventory for growing sales and international markets / and NanoCBD launch
- ensuring adequate funding to cover any potential COVID related regulatory delay.

¹ Medlab may decide to accept applications (in whole or part) that result in the SPP raising more or less than this amount in its absolute discretion.



Timing Considerations

The Offer will be undertaken in accordance with the below timetable. However, Medlab reserves the right to vary the dates and times set out below subject to the Corporations Act and other applicable laws.

Events	Dates
Record Date (being the business day prior to Medlab's announcement of the Plan)	5pm (Sydney time), Friday, 12 June 2020
Opening Date	9am (Sydney time) Wednesday, 17 June 2020
Closing Date	5pm (Sydney time) Friday, 3 July 2020
Issue Date	Tuesday, 7 July 2020
Date on which Shares issued under the Offer are expected to commence trading on the ASX	Wednesday, 8 July 2020
Despatch of holding statements in respect of Shares issued under the Offer	Thursday, 9 July 2020

To participate in the Offer, you should either:

- (a) complete and return your enclosed Application Form in accordance with the details on the Application Form, together with your cheque, bank draft or money order drawn on an Australian bank in Australian dollars; or
- (b) pay via BPAY® online or by telephone (for Shareholders with an eligible Australian bank account only).

Further Information

In accordance with the enclosed terms and conditions (**Terms and Conditions**), the Offer is non-renounceable and Shares in Medlab may be issued under the Offer only to Eligible Shareholder to whom they are offered.

Further details in relation to the Offer are set out in the accompanying documentation, including the Terms and Conditions.

In deciding whether to participate in the Offer, you should seek your own independent financial, legal and taxation advice in respect of the Offer. No cooling off regime applies to the acquisition of ordinary shares in Medlab under the Offer.

On behalf of the Board, I thank you for your continued support in Medlab and I invite you to consider participating in the Offer.

Yours faithfully

Michael Hall
Chairman
Medlab Clinical Limited



1. Establishment

The Plan is established pursuant to *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547* and in accordance with the ASIC Regulatory Guide 125 and the ASX Listing Rules. *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547* grants relief from the requirement to prepare a prospectus for the offer of Shares under the Plan, subject to the satisfaction of certain conditions.

The Plan is also established and offered pursuant to the *Class Waiver Decision – Temporary Extra Placement Capacity* under the ASX Listing Rules which facilitates offers under a Share Purchase Plan that follow on from a Placement. In particular, participants in any Offer made under the Plan should note that the following requirements do not comply:

- (a) the requirement that the Issue Price is not offered at more than a 20% discount to the volume weighted average price of Shares traded on ASX over the 5 trading days up to the last day of trading of Shares on ASX prior to Medlab's announcement of the Plan; and
- (b) the requirement that the number of Shares to be issued under the Plan be not greater than 30% of Medlab's share capital on the last day prior to Medlab's announcement of the Plan.

2. Participation

The Board will make offers under the Plan to all persons who, as at the Record Date, are Eligible Shareholders. As agreed with the ASX, the Board and the executives of Medlab are excluded from participating in the Offer.

You are eligible to participate in the Offer if you were a registered holder of Shares at the Record Date (5pm (Sydney time) on 12 June 2020) with a registered address in Australia (as shown on the Medlab's share register) unless:

- (a) you hold shares on behalf of another person who resides outside Australia in which case you will not be eligible to participate in respect of the Shares of that person; or
- (b) you are, or are acting for the account or benefit of a U.S. Person as defined in Regulation S under the US Securities Act of 1933, as amended (**U.S. Person**).

Medlab has determined that it is not practical for a holder of Shares with a registered address (as shown on the Medlab's share register) in any jurisdiction other than Australia to participate in the Offer. No Offer is made to persons who are not Eligible Shareholders.

Participation in the Offer by Eligible Shareholder is optional and is subject to these Terms and Conditions.

3. Offer

3.1 Nature of Offer

The Offer is non-renounceable and Shares may be issued under the Plan only to Eligible Shareholders to whom they are offered.

The Offer will be made on the same terms and conditions to each Eligible Shareholder. For the avoidance of doubt, all Eligible Shareholders will receive the same offer, irrespective of the number of Shares which they hold on the Record Date.



3.2 Plan participation rules

The following rule apply to participation by Eligible Shareholders.

Single Holders

Unless a holder is a Custodian, each Eligible Shareholder is entitled to apply under the Offer for up to a maximum amount of AUD30,000 worth of Shares (irrespective of whether the holder receives multiple offer documents under the Plan, for example, due to multiple registered sole or joint holdings), subject to the holder certifying that the total of the application price for the following does not exceed AUD30,000:

- (a) the Shares the subject of the application;
- (b) any other Shares applied for by the holder under the Plan or any similar arrangement in the 12 months before the application;
- (c) any other Shares which the holder has instructed a Custodian to acquire on their behalf under the Plan; and
- (d) any other Shares issued to a Custodian under an arrangement similar to the Plan on the 12 months before the application as a result of an instruction given by the holder to the Custodian or another Custodian which resulted in the holder holding beneficial interests in the Shares.

By completing and submitting an application for the Shares under the Offer, a holder certifies the above.

Joint Holders

Unless a holder is a Custodian, if an Eligible Shareholder is recorded with one or more persons as joint holder of Shares, that joint holding is considered to be a single registered holding for the purpose of the Plan and certifications or representations given by a joint holder are taken to have been given by all joint holders. Joint holders are only entitled to participate in the Offer in respect of that single holding. If the same joint holders receive more than one offer document under the Plan due to multiple identical holdings, the joint holders may only apply for one maximum amount of AUD30,000 worth of Shares.

Custodians

If an Eligible Shareholder holds Shares as Custodian, the Offer is made to the Custodian and, subject to a number of conditions, the Custodian has the discretion to extend the Offer to the Beneficiaries. The Custodian may apply for up to a maximum amount of AUD30,000 worth of Shares in respect of each Beneficiary, however, Medlab will not allocate Shares under the Offer to the Custodian unless the Custodian certifies the matters set out in clause 3.2 – 'Single Holder' of *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547* in a Custodian Certificate, which it will need to provide to Advanced Share Registry in conjunction with its application.

Custodians wishing to participate in the Offer on behalf of one or more Beneficiaries should contact Advanced Share Registry on 1300 113 258 to obtain further information on how to apply and how to obtain a Custodian Certificate. If a Custodian holds Shares jointly on behalf of two or more Beneficiaries, the AUD30,000 limit applies jointly in relation to those Beneficiaries as if the Custodian held the Shares on behalf of a single person.

A Custodian must not participate in the Plan if their participation in the Plan would breach *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547*.

3.3 Other Terms

The Offer opens at 9am on 17 June 2020. Under the Offer you may apply for shares up to a maximum of AUD30,000 (subject to scale back described further below). The Offer will be made subject to any other terms and conditions that the Board thinks fit.



4. Issue Price

In accordance with *Class Waiver Decision – Temporary Extra Placement Capacity* under the ASX Listing Rules, the Shares will be issued at an price which is AUD\$0.15 per Share (**Issue Price**) being a price which is not greater than that offered under the Placement.

Important Note: Shareholders should note that there is a risk that the market price of Shares may change between the date of the Offer and the date on which the Shares are issued pursuant to the Plan. This means it is possible that, between the time you make your application and the date on which Shares are issued pursuant to the Plan, you may be able to buy Shares at a lower price than the Issue Price. No cooling-off regime applies in relation to the application for or acquisition of Shares under the Plan.

Medlab recommends that you monitor the Share price and any Medlab announcements, which can be found on Medlab's website <http://www.medlab.co> or on ASX's website at <http://www.asx.com.au>.

5. Costs of Participation

No brokerage, commissions, stamp duty or other transaction costs will be payable by Eligible Shareholders in respect of the application for, and issue of, Shares under the Plan.

6. Acceptance of Offers

6.1 Payment Method

If you wish to participate in the Offer, you need to do one of the following:

Option 1 – Payment by cheque, bank draft or money order

If you are paying for Shares by cheque, bank draft or money order, please complete and return your Application Form, together with your cheque, bank draft or money order, by no later than the Closing Date (**5pm, 3 July 2020**), to:

Advanced Share Registry Ltd

PO Box 1156

Nedlands

Western Australia 6909

Cheques, bank drafts and money orders must be made payable in Australian dollars to 'Medlab Clinical Limited', crossed 'Not Negotiable' and must be drawn on an Australian bank. Cash is not accepted.

Payment will be processed on the day of receipt and as such, sufficient cleared funds must be held in your account, as cheques, bank drafts and money orders received may not be represented and may result in your application being rejected.

Option 2 – Payment by BPAY®

For Eligible Shareholders with an Australian bank account, you may apply for Shares under the Offer by making a BPAY® payment on the internet or by telephone by using the personalised BPAY® reference number shown on your Application Form which is required to identify your holding.

If you are paying for Shares via BPAY® you do not need to return your Application Form, but are taken to make the certifications and representations described in these Terms and Conditions and the Application Form. However, Custodians applying for Beneficiaries must still complete and return a Custodian Certificate.



Payment must be received by no later than the Closing Date. You should be aware that your own financial institution may implement earlier cut-off times with regard to electronic payment, and you should therefore take this into consideration when making payment. It is your responsibility to ensure that funds submitted through BPAY® are received by the Closing Date.

6.2 Further Information

For the avoidance of doubt, applications must be received by the Closing Date. Applications received after that time will not be accepted.

If you have more than one holding of Shares and consequently receive more than one Application Form, when applying for Shares in respect of one of those shareholders you must only use the customer reference number specific to that shareholder as set out in the relevant Application Form. Do not use the same customer reference number for more than one of your shareholdings. This can result in your application monies being applied to your application in respect of only one of your shareholders (with the result that any application in respect of your remaining shareholdings will not be recognised as valid).

If one or more Application Forms are received under the Plan from an Eligible Shareholder in relation to Shares with a value greater than AUD30,000 in any 12 month period, the Shareholder will be issued with the maximum number of Shares permitted by the Plan and the terms of the Offer. Any excess subscription monies will be refunded to the Eligible Shareholder (without interest) as soon as reasonably practicable following allocation.

If an Eligible Shareholder subscribes for an amount which is not exactly divisible by the Issue Price, in calculating the number of Shares to be issued, all fractional entitlements will be rounded down to the nearest whole number of Shares. Medlab will not refund any resulting small excess in subscription monies (i.e. AUD0.20 or less) which will be deemed to form part of the aggregate issue price for the Shares.

6.3 Board Resolution

Notwithstanding any other provision of these Terms and Conditions, the Board may, at its absolute discretion, accept, reject, correct or amend your application for Shares under the Offer, including, without limitation, if:

- (a) the Application Form is incomplete, incorrectly filled out or accompanied by a cheque, bank draft or money order which is not paid in full on first presentation;
- (b) the BPAY® payment received in respect of your application is for less than the full, requisite amount;
- or
- (c) the Board is not reasonably satisfied that you are an Eligible Shareholder.

7. Oversubscriptions and Scale Back

The amount that each Eligible Shareholder may apply for under the Plan is capped at AUD30,000. The Plan aims to raise up to AUD4,000,000. The Board may decide to accept applications (in whole or part) that result in the Plan raising more or less than this amount in its absolute discretion.

Subject to complying with applicable laws, *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547*, and the *Class Waiver Decision – Temporary Extra Placement Capacity*, Medlab reserves the right to close the Offer early or to scale back applications in its sole and absolute discretion.

If applications from Eligible Shareholders for participation in the Plan in aggregate exceed any limit determined by the Board, the Board will scale back applications to the extent and in the manner that is permitted under the *Class Waiver Decision – Temporary Extra Placement Capacity* (as the Board sees fit), including on a pro-rata basis to all participants in the Offer based on either the size of an Eligible



Shareholder's holding as at the Record Date or the number of Shares that the Eligible Shareholder has applied for.

If the Board places a limit on the number of Shares to be issued under this Plan, the Board will use all reasonable endeavours to ensure that participants in the Offer have a reasonable opportunity to participate equitably in the overall capital raising and will notify participants in the Offer why a limit was agreed and how the limit was determined in relation to the total proposed fundraising.

If there is a scale-back, Eligible Shareholders may receive less Shares than the number of Shares for which they applied. If a scale-back produces a fractional number of Shares when applied to a particular parcel, the number of Shares allocated to an Eligible Shareholder will be rounded down to the nearest whole number of Shares.

In the event of a scale back, the difference between the application monies received, and the number of Shares allocated to you under the offer multiplied by the Issue Price, will be refunded to you, without interest, as soon as reasonably practicable following allocation.

8. Issue of Shares

Medlab intends to issue Shares pursuant to the Offer on the Issue Date (7 July 2020).

All Shares issued under the Plan will rank equally in all respects with all Shares on issue as at the date of issue and will carry the same voting rights, dividend rights and other entitlements as those Shares.

Medlab will apply for Shares issued under the Plan to be quoted on ASX. It is expected that they will be quoted on ASX shortly after the Issue Date.

Medlab will, within the period required by the ASX Listing Rules, send Eligible Shareholders, whose application has been accepted by the Board, a holding statement in respect of any Shares issued to them under the Plan.

9. Acknowledgements

If you apply to participate in the offer by submitting a BPAY® payment or completing an returning the Application Form, you will be deemed to have represented on behalf of each person on whose account you are acting that:

- (a) you acknowledge that you are, and each person whose account you are acting is, an Eligible Shareholder;
- (b) you agree that your application is made on, and you agree to be bound by, these Terms and Conditions and the terms and conditions set out in the Application Form and Medlab's constitution;
- (c) you declare that all details and statements in your Application Form are true and complete and not misleading;
- (d) your application is irrevocable and unconditional;
- (e) Medlab may in its sole and absolute discretion scale back any application and/or participation in the Plan to the extent and in the manner it sees fit;
- (f) if there is a scale back (at the Medlab's sole and absolute discretion) you may receive less than the number of Shares for which you have applied;
- (g) if your application results in a fractional number of Shares, the number of Shares you will be allotted (subject to the other terms of the Offer, including in relation to any scale back) will be rounded down to the nearest whole number of Shares;
- (h) the Shares have not been, and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdictions in the United States, or in any other jurisdiction outside Australia and accordingly, the Shares may not be offered, sold or otherwise transferred except in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and any other applicable securities laws;



- (i) you have not and will not send any materials relating to the Offer to any person in the United States or that is, or is acting for the account or benefit of a U.S. Person;
- (j) that the total of the application price for the following does not exceed AUD30,000:
 - (i) the Shares the subject of the application;
 - (ii) any other Shares applied for by the holder under the Plan or any similar arrangement in the 12 months before the application;
 - (iii) any other Shares which the holder has instructed a Custodian to acquire on their behalf under the Plan; and
 - (iv) any other Shares issued to a Custodian under an arrangement similar to the Plan in the 12 months before the application as a result of an instruction given by the holder to the Custodian or another Custodian which resulted in the holder holding beneficial interests in the Shares;
- (k) you are in compliance with all relevant laws and regulations (including, without limitation, section 1043A of the Corporations Act (insider trading) and laws and regulations designed to restrict terrorism financing and. Or money laundering);
- (l) you are not a 'designated person' or 'designated entity' (or other like term) for the purpose of any domestic or international law or regulation implementing United Nations sanctions; and
- (m) you acknowledge that the market price of the Shares may change between the date of the Offer and the date on which Shares are issued pursuant to the Plan, and that the price you pay per Share pursuant to the Offer may exceed the market price of the Shares at the time the Shares are issued, or otherwise allocated, to you under the Offer.

10. Miscellaneous

10.1 Amendment, suspension and termination of the Plan

The Board may, in its discretion, amend, suspend or terminate the Plan at any time and adopt any administrative procedures it thinks appropriate in relation to the Plan. Medlab will notify ASX of any amendment, suspension or termination of the Plan, but failure to do so will not invalidate the amendment, suspension or termination.

Without limiting any other provision of these Terms and Conditions, the Board may vary the timetable for the Offer, including the Closing Date.

Medlab may issue to any person fewer Shares than subscribed for under the Plan (or none at all), including, if Medlab believes that the issue of those Shares would contravene any law (in any jurisdiction) or the rules of any financial market on which Shares are quoted.

10.2 Administration and Dispute Resolution

Medlab's principal objective in administering the Plan is to facilitate participation consistent with compliance with *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547* and all applicable laws and efficient administrative practices. The Board may adopt any administrative procedures it thinks appropriate (from time to time) in relation to the Plan.

Medlab may settle, in any manner it thinks fit, any difficulties, anomalies or disputes which may arise under or in connection with the operation of the Plan, whether generally or in relation to any participant or class of participants, offer, application or Shares, and the decision of Medlab shall be conclusive and binding on all participants and other persons to whom the determination relates.

Medlab reserves the right to waive compliance with any provision of these Terms and Conditions.

10.3 Notices

Notices and statements to Eligible Shareholders may be given in any manner determined by the Board from time to time.



10.4 Privacy

Chapter 2C of the Corporations Act required information about Shareholders (including names, address and details of the shares held) to be included in the Medlab's public register. If a Shareholder ceases to be a Shareholder, Chapter 2C of the Corporations Act required this information to be retained in the Medlab's public register. These statutory obligations are not altered by the Privacy Act 1988 (Cth) as amended. Information is collected to administer Shareholders' security holdings.

10.5 No U.S. Securities Act Registration

This document does not constitute an offer to sell, or the solicitation of an offer to buy, securities in the United States. The Shares have not been and will not be registered under the US Securities Act, or the securities laws of any state or other jurisdiction of the United States and may not be directly or indirectly, offered, sold or resold to:

- (a) a U.S. Person or a persona acting for the account or benefit of a U.S. Person; or
- (b) a person within the United States or a person acting for the account or benefit of a person within the United States.

Because of these legal restrictions, and consistent with the representations contained in these Terms and Conditions and the Application Form, you must not:

- (a) send copies of these Terms and Conditions or any other material relating to the Offer to any person in the United States or who is, or is acting for the account or benefit of the U.S. Persons; or
- (b) submit an Application Form or make payment by BPAY® or otherwise for Shares for any person in the United States or who is, or is acting for the account or benefit of U.S. Persons.

10.6 No Financial Product Advice

Medlab is not licensed to provide financial product advice in relation to the Shares issued under the Plan or any other financial products. No cooling off regime applies in respect of the acquisition of Shares under the Plan (whether the regime is provided for by law or otherwise). Eligible Shareholders should obtain their own advice on whether or not to participate in the Plan.

10.7 Governing Law

The Offer is governed by the law in force in New South Wales. By accepting the Offer you submit to the non-exclusive jurisdiction of the courts of New South Wales.



11. Glossary

Capitalised terms in these Terms and Conditions have the meaning set out below unless the context otherwise requires.

Application Form	Means the personalised application form enclosed with these Terms and Conditions.
ASIC	means the Australian Securities and Investments Commission.
ASX	means ASX Limited or its financial market, the Australian Securities Exchange, as the context requires.
ASX Listing Rules	means the listing rules of ASX as they are amended from time to time.
Beneficiary	means a person who resides in Australia for whom a Custodian (being an Eligible Shareholder) held Shares or behalf of on the Record Date, and who is not, or is not acting for the account or benefit of a U.S. Person.
Board	means the board of directors of Medlab from time to time.
Corporations Act	means the <i>Corporations Act 2001 (Cth)</i> .
Custodian	has the meaning given to that term in paragraph 4 of <i>ASIC Corporations (Share and Interest Purchase Plan) Instrument 2019/547</i> .
Custodian Certificate	means a certificate complying with paragraph 8 of <i>ASIC Corporations (Share and Interest Purchase Plan) Instrument 2019/547</i> .
Eligible Shareholder	has the meaning given to that term in clause 2 of these Terms and Conditions.
Issue Date	means 7 July 2020.
Issue Price	has the meaning give to that term in clause 4 of these Terms and Conditions.
Medlab	means Medlab Clinical Limited (ACN 169 149 071).
Offer	means the offer of Shares under the Plan to Eligible Shareholders.
Placement	means the placement of Shares to institutional and sophisticated investors that closed on 15 June 2020.
Plan	means the share purchase plan which is the subject of these Terms and Conditions.
Record Date	means 12 June 2020.
Share	means a fully paid ordinary share in the capital of Medlab.
Shareholder	means a holder of one or more Shares.
Terms and Conditions	means the terms and conditions set out in this document.
U.S. Person	has the meaning given to that term in clause 2(b) of these Terms and Conditions.



This page was left blank intentionally.